Evaluation of the nature, severity, likelihood and preventability of medication-related hospital-acquired complications
Martin Canning
A B , Chui Han Lee A , Richard Bolitho A and Erin Dunn A
A The Prince Charles Hospital, Metro North Hospital and Health Service, Queensland Health, Rode Road, Chermside, Qld 4032, Australia. Email: Chui.Lee@health.qld.gov.au; Richard.Bolitho@health.qld.gov.au; Erin.Dunn@health.qld.gov.au
B Corresponding author. Email: Martin.Canning@health.qld.gov.au
Australian Health Review 44(6) 935-940 https://doi.org/10.1071/AH19215
Submitted: 23 September 2019 Accepted: 1 February 2020 Published: 17 November 2020
Abstract
Objective Pricing for safety and quality was introduced into Australian hospitals using a defined list of hospital-acquired complications (HACs). Medication-related HACs include drug-related respiratory complications (DRRC), haemorrhagic disorder due to circulating anticoagulants (HDDCA) and hypoglycaemia. The aim of this study was to determine the probability, severity and preventability of medication-related HACs, common contributory medications and themes, and whether medication-related HACs are a suitable data source to inform risk associated with medicines use.
Methods Medical notes were reviewed retrospectively for all patients discharged from a tertiary referral metropolitan hospital between 1 July and 31 December 2018 who were flagged as experiencing a medication-related HAC. Naranjo, Hartwig’s and Schumock and Thornton tools were used to assess the probability, severity and preventability of medication-related HACs.
Results Over the 6-month period, 88 patients experienced a medication-related HAC. An HAC was not identified in five (5.7%) patient charts. The most common HAC was hypoglycaemia (n = 59; 67%), followed by HDDCA (n = 23; 26%) and DRRC (n = 6; 7%). Fifteen patients (17%) flagged with a hypoglycaemia HAC were not on a medicine associated with hypoglycaemia. Overall, 6% (n = 4) of HACs were severe, 72% (n = 49) were moderate and 22% (n = 15) were mild. Where the HAC and causal medication(s) were identified (n = 68), over half were probable (51.5%, n = 35) and 44.1% (n = 30) were possible causes of the adverse drug reaction; only two (2.9%) were definite causes. None of the DRRC HACs was preventable. Over half the HDDCA HACs (52.2%; n = 12) and almost half the hypoglycaemia HACs (46.2%; n = 18) were not preventable. Common themes included appropriate anticoagulant agent, dose and monitoring, as well as periprocedural hypoglycaemic management, which considers oral intake and comorbidities.
Conclusion Not all patients who experience medication-related HACs were on causative medications. Of those who were, medications were probable causal agents in over 50% of cases. Only a small number of HACs were severe and under half of medication-related HACs were preventable.
What is known about the topic? The relationship between pricing for safety and quality and improvements in patient outcomes has shown mixed results. Medication-related harm is a problem within Australia and system-wide changes should be considered to improve patient care.
What does this paper add? This paper adds evidence to the use of medication-related HACs as a source of data to inform risk associated with medicines use and provides details on the preventability and severity of medication-related HACs and the likelihood that medicines contribute to these complications.
What are the implications for practitioners? This paper provides clinicians and policy makers details on the utility of using medication-related HACs as a measure of risk associated with medicines use. It discusses merit in using HACs as a source for quality improvement, but recommends that definitions may need to be reviewed to enhance utility.
References
[1] Australian Commission on Safety and Quality in Health Care (ACSQHC). Hospital-acquired complications information kit. Sydney: ACSQHC; 2018.[2] Australia Commission on Safety and Quality in Health Care (ACSQHC). Hospital-acquired complications (HACs) list – specifications – version 2.0. Sydney: ACSQHC; 2019. Available at: https://safetyandquality.govcms.gov.au/publications-and-resources/resource-library/hospital-acquired-complications-hacs-list-specifications-version-20 [verified 17 September 2019].
[3] Jackson T, Fong A, Liu M, Murray K, Walz L, Houston C, Walker K, Dean S. Incremental costs of hospital-acquired complications in Alberta, Canada. BMC Health Serv Res 2011; 11 A15
| Incremental costs of hospital-acquired complications in Alberta, Canada.Crossref | GoogleScholarGoogle Scholar |
[4] Wasfy JH, Zigler CM, Choirat C, Wang Y, Dominici F, Yeh RW. Readmission rates after passage of the hospital readmissions reduction program: a pre-post analysis. Ann Intern Med 2017; 166 324–31.
| Readmission rates after passage of the hospital readmissions reduction program: a pre-post analysis.Crossref | GoogleScholarGoogle Scholar | 28024302PubMed |
[5] Thirukumaran CP, Glance LG, Rosenthal MB, Temkin-Greener H, Balkissoon R, Mesfin A, Li Y. Impact of Medicare’s nonpayment program on venous thromboembolism following hip and knee replacements. Health Serv Res 2018; 53 4381–402.
| Impact of Medicare’s nonpayment program on venous thromboembolism following hip and knee replacements.Crossref | GoogleScholarGoogle Scholar | 30022482PubMed |
[6] Lee GM, Kleinman K, Soumerai SB, Tse A, Cole D, Fridkin SK, Horan T, Platt R, Gay C, Kassler W, Goldmann DA, Jernigan J, Jha AK. Effect of nonpayment for preventable infections in U.S. hospitals. N Engl J Med 2012; 367 1428–37.
| Effect of nonpayment for preventable infections in U.S. hospitals.Crossref | GoogleScholarGoogle Scholar | 23050526PubMed |
[7] Hartwig SC, Siegel J, Schneider PJ. Preventability and severity assessment in reporting adverse drug reactions. Am J Hosp Pharm 1992; 49 2229–32.
| 1524068PubMed |
[8] Schumock GT, Thornton JP. Focusing on the preventability of adverse drug reactions. Hosp Pharm 1992; 27 538
| 10118597PubMed |
[9] Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, Janecek E, Domecq C, Greenblatt DJ. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30 239–45.
| A method for estimating the probability of adverse drug reactions.Crossref | GoogleScholarGoogle Scholar | 7249508PubMed |
[10] World Health Organization (WHO). Medication safety in high-risk situations. Geneva: WHO; 2019.
[11] World Health Organization (WHO). Promoting rational use of medicines: core components. WHO policy perspectives on medicines no. 5. Geneva: WHO; 2002.
[12] Falconer N, Barras M, Martin J, Cottrell N. Defining and classifying terminology for medication harm: a call for consensus. Eur J Clin Pharmacol 2019; 75 137–45.
| Defining and classifying terminology for medication harm: a call for consensus.Crossref | GoogleScholarGoogle Scholar | 30310967PubMed |
[13] Hohl CM, Karpov A, Reddekopp L, Doyle-Waters M, Stausberg J. ICD-10 codes used to identify adverse drug events in administrative data: a systematic review. J Am Med Inform Assoc 2014; 21 547–57.
| ICD-10 codes used to identify adverse drug events in administrative data: a systematic review.Crossref | GoogleScholarGoogle Scholar | 24222671PubMed |
[14] Jackson TJ, Michel JL, Roberts RF, Jorm CM, Wakefield JG. A classification of hospital-acquired diagnoses for use with routine hospital data. Med J Aust 2009; 191 544–8.
| A classification of hospital-acquired diagnoses for use with routine hospital data.Crossref | GoogleScholarGoogle Scholar | 19912086PubMed |
[15] Shepheard J, Lapiz E, Read C, Jackson TJ. Reconciling hospital-acquired complications and CHADx+ in Victorian coded hospital data. Health Inf Manag 2019; 48 76–86.
| 29690788PubMed |
[16] Australian Commission on Safety and Quality in Health Care (ACSQHC). National Safety and Quality Health Service Standards. 2nd edn. Sydney: ACSQHC; 2017.
[17] Westbrook JI, Li L, Lehnbom EC, Baysari MT, Braithwaite J, Burke R, Conn C, Day RO. What are incident reports telling us? A comparative study at two Australian hospitals of medication errors identified at audit, detected by staff and reported to an incident system. Int J Qual Health Care 2015; 27 1–9.
| What are incident reports telling us? A comparative study at two Australian hospitals of medication errors identified at audit, detected by staff and reported to an incident system.Crossref | GoogleScholarGoogle Scholar | 25583702PubMed |
[18] Parikh S, Christensen D, Stuchbery P, Peterson J, Hutchinson A, Jackson T. Exploring in-hospital adverse drug events using ICD-10 codes. Aust Health Rev 2014; 38 454–60.
| Exploring in-hospital adverse drug events using ICD-10 codes.Crossref | GoogleScholarGoogle Scholar | 24870209PubMed |
[19] Australian Commission on Safety and Quality in Health Care (ACSQHC). APINCHS classification of high risk medicines. Sydney: ACSQHC; 2019. Available at: https://www.safetyandquality.gov.au/our-work/medication-safety/high-risk-medicines/apinchs-classification-high-risk-medicines [verified 17 September 2019].
[20] Ng J, Andrew P, Muir P, Greene M, Mohan S, Knight J, Hider P, Davis P, Seddon M, Scahill S, Harrison J, Zhou L, Selak V, Lawes C, Galgali G, Broad J, Crawley M, Pevreal W, Houston N, Brott T, Ryan D, Peach J, Brant A, Bramley D. Feasibility and reliability of clinical coding surveillance for the routine monitoring of adverse drug events in New Zealand hospitals. N Z Med J 2018; 131 46–60.
| 30359356PubMed |
[21] Independent Hospital Pricing Authority (IHPA). Pricing and funding for safety and quality – risk adjustment model for hospital acquired complications – version 3. Sydney: IHPA; 2018.
[22] Phillips AL, Nigro O, Macolino KA, Scarborough KC, Doecke CJ, Angley MT, Shakib S. Hospital admissions caused by adverse drug events: an Australian prospective study. Aust Health Rev 2014; 38 51–7.
| Hospital admissions caused by adverse drug events: an Australian prospective study.Crossref | GoogleScholarGoogle Scholar | 24351707PubMed |
[23] Parameswaran Nair N, Chalmers L, Bereznicki BJ, Curtain C, Peterson GM, Connolly M, Bereznicki LR. Adverse drug reaction-related hospitalizations in elderly Australians: a prospective cross-sectional study in two Tasmanian hospitals. Drug Saf 2017; 40 597–606.
| Adverse drug reaction-related hospitalizations in elderly Australians: a prospective cross-sectional study in two Tasmanian hospitals.Crossref | GoogleScholarGoogle Scholar | 28382494PubMed |
[24] Ferner RE, Aronson JK. Preventability of drug-related harms – part I: a systematic review. Drug Saf 2010; 33 985–94.
| Preventability of drug-related harms – part I: a systematic review.Crossref | GoogleScholarGoogle Scholar | 20925436PubMed |
[25] Aronson JK, Ferner RE. Preventability of drug-related harms – part II: proposed criteria, based on frameworks that classify adverse drug reactions. Drug Saf 2010; 33 995–1002.
| Preventability of drug-related harms – part II: proposed criteria, based on frameworks that classify adverse drug reactions.Crossref | GoogleScholarGoogle Scholar | 20925437PubMed |
